{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:37:49Z","timestamp":1771263469765,"version":"3.50.1"},"reference-count":72,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[1995,4,15]]},"abstract":"<jats:p>\n            <jats:italic>Background<\/jats:italic>\n            There has been a continuing debate about the overall benefit of cholesterol lowering. We performed a novel meta-analysis of all randomized trials of more than 2 years\u2019 duration (n=35 trials) to describe how coronary-heart-disease (CHD), non-CHD, and total mortality are related to cholesterol lowering and to type of intervention.\n          <\/jats:p>\n          <jats:p>\n            <jats:italic>Methods and Results<\/jats:italic>\n            The analytic approach was designed to separate the effects of cholesterol lowering itself from the other effects of the different types of intervention used. For every 10 percentage points of cholesterol lowering, CHD mortality was reduced by 13% (\n            <jats:italic>P<\/jats:italic>\n            &lt;.002) and total mortality by 10% (\n            <jats:italic>P<\/jats:italic>\n            &lt;.03). Cholesterol lowering had no effect on non-CHD mortality. Certain types of intervention had specific effects independent of cholesterol lowering. Fibrates (clofibrates, 7 trials; gemfibrozil, 2 trials) increased non-CHD mortality by about 30% (\n            <jats:italic>P<\/jats:italic>\n            &lt;.01) and total mortality by about 17% (\n            <jats:italic>P<\/jats:italic>\n            &lt;.02). Hormones (estrogen, 2 trials; dextrothyroxin, 2 trials) increased CHD mortality in men by about 27% (\n            <jats:italic>P<\/jats:italic>\n            &lt;.04), non-CHD mortality by about 55% (\n            <jats:italic>P<\/jats:italic>\n            &lt;.03), and total mortality by about 33% (\n            <jats:italic>P<\/jats:italic>\n            &lt;.01). No specific effects independent of cholesterol lowering were found due to diet (n=11) or other interventions (resins, 5; niacin, 3; statins, 2; partial ileal bypass, 1).\n          <\/jats:p>\n          <jats:p>\n            <jats:italic>Conclusions<\/jats:italic>\n            The results suggest that cholesterol lowering itself is beneficial but that specific adverse effects of fibrates and hormones increase the risk of CHD (hormones only), non-CHD, and total mortality.\n          <\/jats:p>","DOI":"10.1161\/01.cir.91.8.2274","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T00:34:42Z","timestamp":1339461282000},"page":"2274-2282","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":139,"title":["Cholesterol Reduction Yields Clinical Benefit"],"prefix":"10.1161","volume":"91","author":[{"given":"A. Lawrence","family":"Gould","sequence":"first","affiliation":[{"name":"From Merck Research Laboratories, West Point, Pa (A.L.G., N.C.S., J.F.H.); the National Institutes of Health, Bethesda, Md"},{"name":"(J.E.R.); and Bowman Gray School of Medicine, Winston-Salem, NC (C.D.F.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques E.","family":"Rossouw","sequence":"additional","affiliation":[{"name":"From Merck Research Laboratories, West Point, Pa (A.L.G., N.C.S., J.F.H.); the National Institutes of Health, Bethesda, Md"},{"name":"(J.E.R.); and Bowman Gray School of Medicine, Winston-Salem, NC (C.D.F.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy C.","family":"Santanello","sequence":"additional","affiliation":[{"name":"From Merck Research Laboratories, West Point, Pa (A.L.G., N.C.S., J.F.H.); the National Institutes of Health, Bethesda, Md"},{"name":"(J.E.R.); and Bowman Gray School of Medicine, Winston-Salem, NC (C.D.F.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F.","family":"Heyse","sequence":"additional","affiliation":[{"name":"From Merck Research Laboratories, West Point, Pa (A.L.G., N.C.S., J.F.H.); the National Institutes of Health, Bethesda, Md"},{"name":"(J.E.R.); and Bowman Gray School of Medicine, Winston-Salem, NC (C.D.F.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curt D.","family":"Furberg","sequence":"additional","affiliation":[{"name":"From Merck Research Laboratories, West Point, Pa (A.L.G., N.C.S., J.F.H.); the National Institutes of Health, Bethesda, Md"},{"name":"(J.E.R.); and Bowman Gray School of Medicine, Winston-Salem, NC (C.D.F.)."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03500230097036"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6935.1025"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6935.1027"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6935.1038"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6935.1038"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6935.1038"},{"key":"e_1_3_2_7_2","first-page":"1039","volume":"308","year":"1994","unstructured":"Sheldon TA. Drug trial deaths cannot be dismissed. BMJ. 1994;308:1039. Letter.","journal-title":"BMJ"},{"key":"e_1_3_2_8_2","first-page":"1039","volume":"308","year":"1994","unstructured":"Millo J. Hidden bias in observational study. BMJ. 1994;308:1039. Letter.","journal-title":"BMJ"},{"key":"e_1_3_2_9_2","first-page":"1039","volume":"308","year":"1994","unstructured":"Sudlow CL, Macleod MR. \u201cCholesterol papers\u201d add to the confusion. BMJ. 1994;308:1039-1040. Letter.","journal-title":"BMJ"},{"key":"e_1_3_2_10_2","first-page":"1040","volume":"308","year":"1994","unstructured":"Heady JA, Morris JN, Oliver MF. . . . and mislead on adverse effects. BMJ. 1994;308:1040. Letter.","journal-title":"BMJ"},{"key":"e_1_3_2_11_2","first-page":"1040","volume":"308","year":"1994","unstructured":"Vine DL, Hastings G. Absolute risk more informative than relative risk. BMJ. 1994;308:1040. Letter.","journal-title":"BMJ"},{"key":"e_1_3_2_12_2","first-page":"1040","volume":"308","year":"1994","unstructured":"Durrington PN. Cholesterol reduction effective in established disease. BMJ. 1994;308:1040. Letter.","journal-title":"BMJ"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6935.1041"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6935.1041"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1988.tb15891.x"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.4.5790.767"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1984.03340270029025"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198711123172001"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.40.10.1069"},{"key":"e_1_3_2_20_2","first-page":"600","volume":"2","year":"1984","unstructured":"Report from the Committee of Principal Investigators. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Lancet. 1984;2:600-604.","journal-title":"Lancet"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92588-7"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1972.03200070084015"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.301.6747.309"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.304.6824.431"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.306.6889.1367"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.305.6844.15"},{"key":"e_1_3_2_27_2","first-page":"109","volume":"28","year":"1993","unstructured":"Cucherat M, Boissel J-P. Meta-analysis of results from clinical trials on prevention of coronary heart disease by lipid-lowering interventions. Clin Trials Meta-Anal. 1993;28:109-129.","journal-title":"Clin Trials Meta-Anal"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.82.6.2242517"},{"key":"e_1_3_2_29_2","first-page":"63","volume":"18","year":"1992","unstructured":"Holme I. Meta-analysis of cholesterol reduction trials: coronary disease and mortality. Primary Cardiol. 1992;18:63-70.","journal-title":"Primary Cardiol"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","unstructured":"Holme I. Relation of coronary heart disease incidence and total mortality to plasma cholesterol reduction in randomized trials: use of meta-analysis. Br Heart J. 1993;69(suppl):S42-S47.","DOI":"10.1136\/hrt.69.1_Suppl.S42"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199010183231606"},{"key":"e_1_3_2_32_2","first-page":"1813","volume":"325","year":"1991","unstructured":"Rossouw JE, Canner PL, Hulley SB. Deaths from injury, violence, and suicide in secondary prevention trials of cholesterol lowering. N Engl J Med. 1991;325:1813. Letter.","journal-title":"N Engl J Med"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6925.351"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6925.373"},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","unstructured":"McCullagh P Nelder JA. Generalized Linear Models. 2nd ed. New York NY: Chapman & Hill; 1989.","DOI":"10.1007\/978-1-4899-3242-6"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780090307"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(78)90076-0"},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","unstructured":"Dayton S Pearce ML Hashimoto S Dixon WJ Tomiyasu UA. A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation. 1969;40(suppl II):II-1-II-63.","DOI":"10.1161\/01.CIR.40.1S2.II-1"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a062065"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1982.03330120023025"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1985.03360150073027"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)91338-6"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199010043231404"},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","unstructured":"Schoch HK. The U.S. Veterans Administration cardiology drug-lipid study: an interim report. In: Holmes WL Carlson LA Paoletti R eds. Drugs Affecting Lipid Metabolism. New York NY: Plenum Press; 1969:405-420.","DOI":"10.1007\/978-1-4615-6866-7_34"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.3109\/07853899309147855"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.4.5790.775"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1975.03240160024021"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(86)80293-5"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(72)90067-6"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(61)92951-8"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)90828-3"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4684-0967-3_18"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(65)91469-8"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5449.1531"},{"key":"e_1_3_2_55_2","first-page":"693","volume":"2","year":"1968","unstructured":"Research Committee to the Medical Research Council. Controlled trial of soyabean oil in myocardial infarction. Lancet. 1968;2:693-700.","journal-title":"Lancet"},{"key":"e_1_3_2_56_2","unstructured":"Leren P. The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction: a controlled clinical trial. Acta Med Scand. 1966;suppl 466:1-92."},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199011083231901"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90863-X"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.69.2.6360414"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1987.03390230069027"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(91)90002-Y"},{"key":"e_1_3_2_62_2","first-page":"400A","volume":"40","year":"1992","unstructured":"Fail PS, Sahni RS, Maniet AR, Voci G, Banka VS. The long-term clinical efficacy of lovastatin therapy following successful coronary angioplasty. Clin Res. 1992;40:400A. Abstract.","journal-title":"Clin Res"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1970.03180070069012"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1973.03230060030009"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1991.00400040020006"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-2-199307150-00008"},{"key":"e_1_3_2_67_2","first-page":"1383","volume":"344","year":"1994","unstructured":"Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.","journal-title":"Lancet"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/77.2.275"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1214\/ss\/1177012906"},{"key":"e_1_3_2_70_2","unstructured":"Flemington TR Harrington DP. Counting Processes and Survival Analysis. New York NY: John Wiley & Sons; 1991."},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780091214"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199305000-00005"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.CIR.91.8.2274","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T15:38:03Z","timestamp":1715528283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.CIR.91.8.2274"}},"subtitle":["A New Look at Old Data"],"short-title":[],"issued":{"date-parts":[[1995,4,15]]},"references-count":72,"journal-issue":{"issue":"8","published-print":{"date-parts":[[1995,4,15]]}},"alternative-id":["10.1161\/01.CIR.91.8.2274"],"URL":"https:\/\/doi.org\/10.1161\/01.cir.91.8.2274","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,4,15]]},"assertion":[{"value":"1994-09-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1994-12-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1995-04-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}